Do bacteria cause exacerbations of COPD?

Chest

Volumn 118, Issue 1, 2000, Pages 193-203

  Hirschmann, Jan V ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antimicrobial therapy; Bacterial infections; COPD exacerbations

Indexed keywords

ANTIINFECTIVE AGENT; VACCINE;

ANTIBIOTIC THERAPY; ANTIBODY TITER; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HUMAN; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; STREPTOCOCCUS PNEUMONIAE;

EID: 0033944282     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.1.193     Document Type: Article

References (81)

1. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998; 352:467-473
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152(suppl):S77-S120
3. Buscho RO, Saxtan D, Shultz PS, et al. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978; 137:377-383
4. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113:465-474
5. McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980; 74:228-238
6. Smith CB, Golden CA, Kanner RE, et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1980; 121:225-232
7. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498-1505
8. Beaty CD, Grayston JT, Wang SP, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:1408-1410
9. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6:19-22
10. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbations of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160:349-353
11. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14:178-182
12. Hyman CL, Roblin PM, Gaydos CA, et al. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis 1995; 20:1174-1178
13. Bourke SJ, Lightfoot NF. Chlamydia pneumoniae: Defining the clinical spectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50(suppl 1):S43-S48
14. Evans AS. Causation and disease: The Henle-Koch postulates revisited. Yale J Biol Med 1976; 49:175-195
15. Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991; 133:635-648
16. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-1022
17. Canadian Thoracic Society Workshop Group. Guidelines for the assessment and management of chronic obstructive pulmonary disease. Can Med Assoc J 1992; 147:420-428
18. Miravitlles M, Mayordomo C, Artes M, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999; 93;173-179
19. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112(suppl):310S-313S
20. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-1320
21. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142:1004-1008
22. Pines A, Raafat H, Greenfield JSB, et al. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972; 66:107-115
23. Berry DG, Fry J, Hindley CP, et al. Exacerbations of chronic bronchitis: Treatment with oxytetracycline. Lancet 1960; 1:137-139
24. Elmes PC, King TKC, Langlands JHM, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. BMJ 1965; 2:904-908
25. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116:40-46
26. Schreiner A, Bjerkestrand G, Digranes A, et al. Bacteriological findings in the transtracheal aspirate from patients with acute exacerbation of chronic bronchitis. Infection 1978; 6:54-56
27. Martinez JA, Rodriguez E, Bastida T, et al. Quantitative study of the bronchial bacterial flora in acute exacerbations of chronic bronchitis [letter]. Chest 1994; 105:976
28. Smith CB, Golden CA, Kanner RE, et al. Haemophilus influenzae and Haemophilus parainfluenzae in chronic obstructive pulmonary disease. Lancet 1976; 1:1253-1255
29. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 1998; 113:1542-1548
30. Mobbs KJ, van Saene HKF, Sunderland D, et al. Oropharyngeal gram-negative bacillary carriage in chronic obstructive pulmonary disease: Relation to severity of disease. Respir Med 1999; 93:540-545
31. Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: A target for N-acetylcysteine therapy? Eur Respir J 1994; 7:94-101
32. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: A bronchoscopic study. Eur Respir J 1997; 10:1137-1144
33. Monsó E, Rosell, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13:338-342
34. Fisher M, Akhtar AJ, Calder MA, et al. Pilot study of factors associated with exacerbations in chronic bronchitis. BMJ 1969; 4:187-192
35. Storey PB, Morgan WKC, Diaz AJ, et al. Chronic obstructive airway disease: Bacterial and cellular content of the sputum. Am Rev Respir Dis 1964; 90:730-735
36. Glynn AA. Antibodies to Haemophilus influenzae in chronic bronchitis. BMJ 1959; 2:911-914
37. Morgan WKC, Wood WH. Antibody response to Haemophilus influenzae in obstructive airway disease. Lancet 1965; 1:1128-1131
38. Ross CAC, McMichael S, Eadie MB, et al. Infective agents and chronic bronchitis. Thorax 1966; 21:461-464
39. Reichek N, Lewin EB, Rhoden DL, et al. Antibody response to bacterial antigens during exacerbations of chronic bronchitis. Am Rev Respir Dis 1970; 101:238-244
40. Gump DW, Christmas WA, Forsyth BR, et al. Serum and secretory antibodies in patients with chronic bronchitis. Arch Intern Med 1973; 132:847-851
41. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Can Assoc Med J 1987; 136:361-365
42. Lehmann D, Coakley KJ, Coakley CA, et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am Rev Respir Dis 1991; 144:324-330
43. Clancy RL, Cripps AW, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med J Aust 1990; 152:413-416
44. Clancy R, Cripps A, Murree-Allen K, et al. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet 1985; 2:1395-1397
45. Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust N Z J Med 1991; 21:427-432
46. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150:1646-1652
47. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152: 1926-1931
48. Marley EF, Campos JM. Haemophilus influenzae infection. In: Connor DH, Chandler FW, Schwartz DA, et al, eds. Pathology of Infectious Diseases. Stamford, CT: Appleton & Lange, 1997; 579-582
49. Kissane JM. Streptococcal infections and infections by "streptococcus-like" organisms. In: Connor DH, Chandler FW, Schwartz DA, et al, eds. Pathology of Infectious Diseases. Stamford, CT: Appleton & Lange, 1997; 817-832
50. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753-758
51. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154:407-412
52. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941-1947
53. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Lancet 1999; 354:456-460
54. American Thoracic Society. Dyspnea: mechanisms, assessment, and management; A consensus statement. Am J Respir Crit Care Med 1999; 159:321-340
55. Elmes PC, Fletcher CM, Dutton AAC. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. BMJ 1957; 2:1272-1275
56. Fear EC, Edwards G. Antibiotic regimes in chronic bronchitis. Br J Dis Chest 1962; 56:153-162
57. Petersen ES, Esmann V, Høncke P, et al. A controlled study of the effect of treatment on chronic bronchitis: An evaluation using pulmonary function tests. Acta Med Scand 1967; 182:293-305
58. Pines A, Raafat H, Plucinski K, et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968; 2:735-738
59. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis: A controlled study using tetracycline. Ann Intern Med 1982; 97:18-21
60. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204
61. Jørgensen AF, Coolidge J, Pedersen PA, et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10:7-11
62. Sachs APE, Koëter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50:758-763
63. Anthonisen NR. Antibiotic therapy and chronic obstructive lung disease. Ann Intern Med 1987; 107:254
64. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis. JAMA 1995; 273:957-960
65. 1 and peak expiratory flow rates among normal and asthmatic subjects. Thorax 1994; 49:775-780
66. Teramoto S, Suzuki M, Hatsui H, et al. Influence of age on diurnal variability in measurements of spirometric indexes and respiratory pressures. J Asthma 1999; 36:487-492
67. Allen JL, Castile RG, Mead J. Positive effort dependence of maximum expiratory flow. J Appl Physiol 1987; 62:718-722
68. Lebowitz MD, Knudson RJ, Robertson G, et al. Significance of intraindividual changes in maximum expiratory flow volume and peak expiratory flow measurements. Chest 1982; 81:566-770
69. Sobol BJ, Emirgil C. Subject effort and expiratory flow rate. Am Rev Respir Dis 1964; 89:402-408
70. Black LF, Offord K, Hyatt RE. Variability in the maximum expiratory flow volume curve in asymptomatic smokers and nonsmokers. Am Rev Respir Dis 1974; 110:282-292
71. McCarthy DS, Craig DB, Cherniak RM. Intraindividual variability in maximum expiratory flow-volume and closing volume in asymptomatic subjects. Am Rev Respir Dis 1975; 112:407-411
72. Phillips H, Van Hook CJ, Butler T, et al. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. Chest 1993; 104:1387-1392
73. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study. Chest 1998; 114:120-130
74. O'Doherty BO, Daniel R. Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:441-446
75. Leophonte P, Baldwin RJT, Pluck N. Trovafloxacin vs amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur J Clin Microbiol Infect Dis 1998; 17:434-440
76. Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 mg of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 mg of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42:114-120
77. Read RC, Kuss A, Berrisoul F, et al. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis. Respir Med 1999; 93:252-261
78. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:722-729
79. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multi-center, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998; 7:101-109
80. Langan CE, Cranfield R, Breisch S, et al. Randomized, double-blind study of grepafloxacin vs amoxicillin patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40:63-72
81. Mertens JCC, van Barneveld PWC, Asin HRG, et al. Double-blind study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1992; 36:1456-1459